Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Carl Dambkowski Sells 4,540 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) insider Carl Dambkowski sold 4,540 shares of the firm's stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $48.76, for a total value of $221,370.40. Following the completion of the sale, the insider now directly owns 258,073 shares of the company's stock, valued at $12,583,639.48. This represents a 1.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, December 4th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.07, for a total value of $307,056.55.
• On Wednesday, November 6th, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The stock was sold at an average price of $59.12, for a total transaction of $394,034.80.
• On Wednesday, October 2nd, Carl Dambkowski sold 6,665 shares of Apogee Therapeutics stock. The shares were sold at an average price of $56.26, for a total transaction of $374,972.90.

Apogee Therapeutics Stock Performance

Shares of APGE stock traded up $0.18 on Friday, hitting $44.50. The stock had a trading volume of 691,879 shares, compared to its average volume of 504,108. The stock's 50 day moving average is $51.43 and its 200-day moving average is $48.28. The firm has a market capitalization of $2.00 billion, a price-to-earnings ratio of -18.39 and a beta of 2.30. Apogee Therapeutics, Inc. has a 52-week low of $20.78 and a 52-week high of $72.29.

Institutional Trading of Apogee Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Apogee Therapeutics in the third quarter worth $71,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Apogee Therapeutics by 21.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company's stock worth $94,000 after buying an additional 285 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Apogee Therapeutics in the 2nd quarter valued at about $143,000. Wexford Capital LP bought a new stake in shares of Apogee Therapeutics during the 3rd quarter valued at about $230,000. Finally, Intech Investment Management LLC acquired a new stake in Apogee Therapeutics during the third quarter worth about $300,000. Institutional investors and hedge funds own 79.04% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They issued a "buy" rating and a $89.00 target price for the company. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research note on Thursday. Wedbush boosted their target price on Apogee Therapeutics from $87.00 to $90.00 and gave the stock an "outperform" rating in a research report on Monday, December 2nd. Finally, Canaccord Genuity Group began coverage on Apogee Therapeutics in a research report on Monday, November 25th. They issued a "buy" rating and a $89.00 price target for the company. Eight research analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics has a consensus rating of "Buy" and an average target price of $83.88.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.